ArticleJournal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology2018
Aptamer-conjugated multi-walled carbon nanotubes as a new targeted ultrasound contrast agent for the diagnosis of prostate cancer.
Article in Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Application Value of Contrast-Enhanced Ultrasound Combined with Enhanced MR Scanning in Patients with Intrahepatic Cholangiocarcinoma.Journal of healthcare engineering · 2022Trial
- Microplastics as both a driver of genitourinary cancers and a deliverer of treatments.Communications medicine · 2026Review
- Developing point-of-need (PON) cancer biosensors using microfluidic paper-based analytical devices: recent advances.RSC advances · 2025Review
- Emerging Trends of Nanomedicines in the Management of Prostate Cancer: Perspectives and Potential Applications.Pharmaceutics · 2024Review
- Carbon-Based Nanostructures as Emerging Materials for Gene Delivery Applications.Pharmaceutics · 2024Review
- Nanomedicines in diagnosis and treatment of prostate cancers: an updated review.Frontiers in bioengineering and biotechnology · 2024Review
- Ultrasound contrast agents from microbubbles to biogenic gas vesicles.Medical review (2021) · 2023Review
- Current applications of nanomaterials in urinary system tumors.Frontiers in bioengineering and biotechnology · 2023Review
- Aptamer-Based Probes for Cancer Diagnostics and Treatment.Life (Basel, Switzerland) · 2022Review
- Dual-Mode Fluorescence/Ultrasound Imaging with Biocompatible Metal-Doped Graphene Quantum Dots.ACS biomaterials science & engineering · 2022Article
- Aptamers as Theragnostic Tools in Prostate Cancer.Biomolecules · 2022Review
- Ultrasound-Responsive Systems as Components for Smart Materials.Chemical reviews · 2022Review
- Aptamers used for molecular imaging and theranostics - recent developments.Theranostics · 2022Review
- The State of the Art of Theranostic Nanomaterials for Lung, Breast, and Prostate Cancers.Nanomaterials (Basel, Switzerland) · 2021Review
- Ultrasound-Responsive Nanocarriers in Cancer Treatment: A Review.ACS pharmacology & translational science · 2021Review
- Recent Advances in Nanomaterial-Based Aptasensors in Medical Diagnosis and Therapy.Nanomaterials (Basel, Switzerland) · 2021Review
- Comprehensive review on ultrasound-responsive theranostic nanomaterials: mechanisms, structures and medical applications.Beilstein journal of nanotechnology · 2021Review
- Carbon Based Nanodots in Early Diagnosis of Cancer.Frontiers in chemistry · 2021Review
- Novel Span-PEG Multifunctional Ultrasound Contrast Agent Based on CNTs as a Magnetic Targeting Factor and a Drug Carrier.ACS omega · 2020Article
- Combination Chemotherapy of Lung Cancer - Co-Delivery of Docetaxel Prodrug and Cisplatin Using Aptamer-Decorated Lipid-Polymer Hybrid Nanoparticles.Drug design, development and therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early diagnosis is primarily important for the therapeutic and prognostic outcomes of malignancies including prostate cancer (PCa). However, the visuality and veracity of ultrasound imaging for the diagnosis and prognostic prediction of PCa remains poor at present. In this study, we developed a new nanoultrasound contrast agent by modifying multi-walled carbon nanotubes (MWCNTs) with polyethylene glycol (PEG) and anti-PSMA aptamer. The result showed that the modified MWCNTs offered better visuality and veracity and were able to target PCa cells more effectively as compared with the traditional contrast agent. The zeta potential was about - 38 mv. The length of this contrast agent was about 400 nm and the diameter of it was about 30 nm. The zeta potential, TEM, and FT-IR all proved the successful preparation of the agent. The vitro cytological study revealed good cell uptake and biocompatibility of the new contrast agent. The minimum detection concentration in vitro is 10 μg/ml. The earliest stage of the detection was under the parameters of frequency = 6.0 MHz and medical index = 0.06. Both in vitro and in vivo ultrasound imaging demonstrated that the new nanoultrasound contrast agent had a good development effect, distribution, and metabolism, and may prove to be a good targeted ultrasound contrast agent, especially for PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.